Evidence map›Paper›PMID 21189470›Full record

ArticleJournal of visualized experiments : JoVE2010

Development of a negative selectable marker for Entamoeba histolytica.

Mayuresh M Abhyankar, Sarah M Haviland, Carol A Gilchrist, William A Petri

Abstract readVideo-Audio Media
In one paragraph

Article in Journal of visualized experiments : JoVE, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mayuresh M AbhyankarDivision of Infectious Disease and International Health, University of Virginia Health System, USA.
Sarah M Haviland
Carol A Gilchrist
William A Petri

Funding

STRUCTURE/FUNCTION OF E HISTOLYTICA ADHERENCE LECTINR01AI026649 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI PETRI, WILLIAM A · 1989 to 2016
$6.1M
UVA Digestive Health Research CenterP30DK067629 · NIDDK · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI PIZARRO, THERESA TORRES · 2004 to 2008
$5.6M
NIAID NIH HHS AI 26649NIAID NIH HHS R01 AI026649NIDDK NIH HHS P30 DK067629
6 · The paper itself

Abstract

Entamoeba histolytica is the causative agent of amebiasis and infects up to 10% of the world's population. The molecular techniques that have enabled the up- and down-regulation of gene expression rely on the transfection of stably maintained plasmids. While these have increased our understanding of Entamoeba virulence factors, the capacity to integrate exogenous DNA into genome, which would allow reverse genetics experiments, would be a significant advantage in the study of this parasite. The challenges presented by this organism include inability to select for homologous recombination events and difficulty to cure episomal plasmid DNA from transfected trophozoites. The later results in a high background of exogenous DNA, a major problem in the identification of trophozoites in which a bona fide genomic integration event has occurred. We report the development of a negative selection system based upon transgenic expression of a yeast cytosine deaminase and uracil phosphoribosyl transferase chimera (FCU1) and selection with prodrug 5-fluorocytosine (5-FC). The FCU1 enzyme converts non-toxic 5-FC into toxic 5-fluorouracil and 5-fluorouridine-5'-monophosphate. E. histolytica lines expressing FCU1 were found to be 30 fold more sensitive to the prodrug compared to the control strain.

Indexed as

Cytosine DeaminaseEntamoeba histolyticaFlucytosinePentosyltransferasesTransfectionTransgenesCytosine DeaminaseFlucytosinePentosyltransferasesuracil phosphoribosyltransferase

Identifiers

PMID21189470
PMCPMC3159661

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.